University of Groningen

Pelvic high-grade serous carcinoma in BRCA1 and BRCA2 mutation carriersReitsma, Welmoed

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite fromit. Please check the document version below.

Document VersionPublisher's PDF, also known as Version of record

Publication date:2013

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):Reitsma, W. (2013). Pelvic high-grade serous carcinoma in BRCA1 and BRCA2 mutation carriers:carcinogenesis and early diagnosis. Groningen: [s.n.].

CopyrightOther than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of theauthor(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policyIf you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediatelyand investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons thenumber of authors shown on this cover page is limited to 10 maximum.

Download date: 02-05-2020

APPENDIX: COLOR FIGURES

189

C. COLOR FIGURES

APPENDIX: COLOR FIGURES

190

CHAPTER 6, FIGURE 1. Expression levels of VEGF-A and ER-α staining in benign and malignant tubal epithelium in respectively a BRCA1 mutation carrier and a non-carrier

HE VEGF-A ER-α

Benign, BRCA1

Benign, non-carrier

Malignant, BRCA1

Malignant, non-carrier

APPENDIX: COLOR FIGURES

191

CHAPTER 8, FIGURE 1. Unsupervised distance matrix clustering analysis of all miRNAs identified as being differentially expressed (BH-adjusted P<0.01 and fold-change ≥1.5x) between PHGSC and benign fallopian tube (dendogram); the level of miRNA expression is color-coded: yellow, higher miRNA expression and blue, lower miRNA expression

APPENDIX: PUBLICATION OVERVIEW

192

D. PUBLICATION OVERVIEW

RELATING TO THIS THESIS Vencken PMLH* and Reitsma W*, Kriege M, Mourits MJE, de Bock GH, de Hullu JA, van Altena AM, Gaarenstroom KN, Vasen HFA, Adank MA, Schmidt MK, van Beurden M, Zweemer RP, Rijcken F, Slangen BFM, Burger CW, Seynaeve C. Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands. Ann Oncol 2013, in press (*both authors contributed equally) Reitsma W, de Bock GH, Oosterwijk JC, Bart J, Hollema H, Mourits MJE. Argumenten ter ondersteuning van de ‘tubahypothese’ in een prospectieve serie van preventief verwijderde tubae en ovaria. Oncologie Uptodate 2013, in press Reitsma W, Mourits MJE, de Bock GH, Hollema H. Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers. Mod Pathol 2012, doi: 10.1038/modpathol.2012.169 Mourits MJE, Reitsma W. Reactie op onderzoek naar oorzaak eierstokkankers van UMC St Radboud. Electronic publication: www.brca.nl, moc/umcg.nl and www.hebon.nl, 2012 Reitsma W, de Bock GH, Oosterwijk JC, Bart J, Hollema H, Mourits MJE. Support of the ‘fallopian tube hypothesis’ in a prospective series of risk-reducing salpingo-oophorectomy specimens. Eur J Cancer 2012;49:132-141 Reitsma W, de Bock GH, Oosterwijk JC, ten Hoor KA, Hollema H, Mourits MJE. Clinicopathologic characteristics and survival in BRCA1- and BRCA2-related adnexal cancer: are they different? Int J Gynecol Cancer 2012;22(4):579-85 Reitsma W, Hollema H, Mourits MJE. Letter commenting on "Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol" in Int J Gynecol Cancer 2011;21:846-851 by C. Bethan Powell et al. Int J Gynecol Cancer 2012;22(1):2

APPENDIX: PUBLICATION OVERVIEW

193

OTHER Reitsma W, Wiegman MJ, Damstra RJ. Penis- und scrotal Lymphödem als eine ungewöhnliche Präsentation von Morbus Crohn: case report und Überprüfung der Literatur. Vasomed 2012;24(6):331-2 Reitsma W, Wiegman MJ, Damstra RJ. Penile and scrotal lymphedema as an unusual presentation of Crohn's disease: case report and review of the literature. Lymphology 2012;45:37-41 Reitsma W, Lammerink EA, Zeeman GG. De diagnose van het baringsbegin: meer dan een definitiekwestie. Ned Tijdschr Geneeskd 2011;155(18):A2273 Reitsma W, van der Lei B, Koning M, Pascal A, Mourits MJE. Verzoek om een schaamlipverkleining: een kwestie van smaak? Ned Tijdschr Seks 2011;35(4): 209-218 Reitsma W, Mourits MJE, Koning M, Pascal A, van der Lei B. No (wo)man is an island - The influence of physicians’ personal predisposition to labia minora appearance on their clinical decision-making: a cross-sectional survey. J Sex Med 2011;8(8):2377-85 Reitsma W, Essen van AJ, Werker PM, Biezen van der JJ. Postaxiale polydactylie. Medisch Contact 2010;18:833 Reitsma W, Beukens S, van Essen AJ, Jansen E. Een vrouw met een katapult-botje: een congenitale metacarpale synostose. Medisch Contact 2010;41:2153 Reitsma W. Verloskunde mooi? Wat een farce. Medisch Contact 2010;43. Electronic publication:http://medischcontact.artsennet.nl/nieuws-26/archief-6/tijdschriftartikel/86434/ver loskunde-mooi-wat-een-farce.htm Reitsma W, Visser JM, de Vries F, van Hengel P. A 64-year-old man with chronic cough and recurrent respiratory infections. Resp Med CME 2009;3:103-5

APPENDIX: AUTHORS AND AFFILIATIONS

194

E. AUTHORS AND AFFILIATIONS From the division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands JUDITH TEN BERGE, BSc KLASKE A TEN HOOR, BSc MARIAN JE MOURITS, MD, PhD From the department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands GEERTRUIDA H DE BOCK, MSc, PhD From the department of Pathology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands JOOST BART, MD, PhD ANKE VAN DEN BERG, MD, PhD HARRY HOLLEMA, MD, PhD From the department of Clinical Genetics, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands JAN C OOSTERWIJK, MD, PhD From the department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands RODRIGO COUTINHO DE ALMEIDA, MSc RUTGER MODDERMAN, BSc SEBO WITHOFF, MSc, PhD From the department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands SIETSKE BM GAYKEMA, MD CAROLINE P SCHRODER, MD, PhD From the division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Erasmus University Medical Center, Rotterdam, the Netherlands CURT W BURGER, MD, PhD PEGGY MLH VENCKEN, MD From the department of Medical Oncology, Family Cancer Clinic, Erasmus University MC-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands MIEKE KRIEGE, MSc, PhD CAROLINE SEYNAEVE, MD, PhD

APPENDIX: AUTHORS AND AFFILIATIONS

195

From the division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University Medical Center St Radboud, Nijmegen, the Netherlands ANNE M VAN ALTENA, MD, PhD JOANNE A DE HULLU, MD, PhD From the division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Leiden University Medical Center, Leiden, the Netherlands KATJA N GAARENSTROOM, MD, PhD From the Netherlands Foundation for the detection of Hereditary Tumours, the Netherlands HANS FA VASEN, MEDICAL DIRECTOR, MD, PhD From the department of Clinical Genetics, VU University Amsterdam, Amsterdam, the Netherlands MURIEL A ADANK, MD, PhD From the division of Psychosocial Research and Epidemiology, Department of Molecular Pathology, NKI-AVL, Amsterdam, the Netherlands MARJANKA K SCHMIDT, MD, PhD From the division of Gynecologic Oncology, Department of Obstetrics and Gynecology, NKI-AVL, Amsterdam, the Netherlands MARC VAN BEURDEN, MD, PhD From the division of Woman and Baby, Department of Gynecologic Oncology, University Medical Center Utrecht, Utrecht, the Netherlands RONALD P ZWEEMER, MD, PhD From the division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Amsterdam Medical Center, Amsterdam, the Netherlands FLEUR RIJCKEN, MD, PhD From the division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Maastricht University Medical Center, Maastricht, the Netherlands BRIGITTE FM SLANGEN, MD, PhD

196